NANJING VAZYME BIOTECH CO

Investors eye Nanjing Vazyme Biotech’s steady 21.52 CNY share price as it hovers near its 200‑day SMA, with a pipeline of recombinant vaccines poised to boost growth.

Explore Nanjing Vazyme Biotech’s latest market snapshot, trading stats, and company profile—discover why investors watch its biotech growth and stock performance.

Read how Nanjing Vazyme Biotech’s Q3 forecast shows a shift to profitability, boosted by high‑margin products and sector confidence, and what that means for investors.